You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • AB0469 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial)

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Abstracts accepted for publication. Rheumatoid arthritis - non biologic treatment and small molecules
AB0469 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Okada M, Matsuno H, Abe C, et al
AB0469 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial)
Annals of the Rheumatic Diseases 2014;73:963.